WASHINGTON (AP) - A panel of U.S. respiratory experts has voted in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravence for treating chronic lung disease.
A majority of Food and Drug Administration panelists voted that the Breo Ellipta inhaler is safe and effective for long-term use and to control flare ups in patients with chronic obstructive pulmonary disorder.
The FDA is not required to follow the group's recommendation, though it often does.
The ailment, often called smoker's cough, can cause a number of breathing problems, including chronic bronchitis and emphysema.
Breo is a combination of two respiratory drugs that help to open lung airways and reduce swelling. The combination drug is designed to be used with the Ellipta inhaler device.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Four members of a Kettering family were killed after fire broke out inside their Craig Drive home early Thursday morning.
Dayton-based PSA Airlines announced it is hiring 1,000 more employees as part an American Airlines announcement that it will be purchasing new regional jets.
A Darke County drug task force arrested two Dayton men Wednesday they said were selling heroin in Greenville.
A bill approved by Ohio lawmakers will make it easier for many adopted Ohioans to get their original birth certificates.
The Tri-State's newest gambling establishment will throw open it's doors Dec. 12 at noon so you can throw down your money.